Papers
2
Total Citations
81
H-Index
2
About
Dr. Lara Dunn is a leading oncologist whose research focuses on treatment deintensification for HPV-associated oropharyngeal cancer (OPC), a rapidly rising malignancy in the United States. Her work addresses the critical challenge of reducing long-term toxicities from chemoradiation while preserving excellent survival outcomes in this radiosensitive, favorable-prognosis patient population. Dr. Dunn’s highly cited 2022 paper, with 57 citations, provides a comprehensive consensus on controversies and future directions for de-escalation strategies. Her 2021 review, cited 24 times, critically analyzes past clinical trial failures—such as substituting cisplatin with cetuximab—while highlighting promising future approaches to safely reduce treatment intensity. By synthesizing evidence from failed and successful trials, Dr. Dunn has shaped the evolving paradigm for managing HPV-positive OPC, directly impacting clinical practice and guiding next-generation studies. Her contributions are essential for researchers and clinicians seeking to balance efficacy with quality of life, making her a pivotal voice in head and neck oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2